What's new in treatment of breast cancer? - Highlights of ESMO BC 2023

Prof. Matteo Lambertini explains the highlights of the 2023 ESMO Breast Cancer Conference. - There are more insights of the toxicity of the new ACD's, paticullary for trastuzumab deruxtecan. Updated data on the DESTINY (DESTINY-Breast04, 02) trials in the terms of toxicities. - CAPItello-291, capivasertib to fulvestrant improves progression-free survival for key subgroups of patients with hormone receptor-positive, HER2-negative advanced breast cancer resistant to aromatase inhibitors. - The updated result of IMpassion031, the authors presented survival outcomes for this studies. - Highlights the result of the recently published positive study about the safety of temporarly interrupting endocrine therapy to attempt pregnancy after breast cancer. Video: https://medicaldigest.org/scientific-contents/interview:whats-new-treatment-breast-cancer-highlights-esmo-bc-2023